UnknownPhase 4

Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS

Egypt60 participantsStarted 2022-01-06

Plain-language summary

The aim of this work is to compare continuous infusion vs on need intermittent boluses of Cisatracurium in the early management of pediatric acute respiratory distress syndrome

Who can participate

Age range1 Month – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Children with mild, moderate, and severe ARDS diagnosed according to criteria of Pediatric Acute Lung Injury Consensus Conference (PALICC) in 2015.
✓. Children of both sexes aged from one month to 18 years.
✓. Children diagnosed with ARDS \<48 hours before enrollment

Exclusion criteria

✕. Continuous neuromuscular blockade at enrollment
✕. Children on phenytoin and carbamazepine
✕. Severe liver cirrhosis
✕. High-risk medical illness (Bone marrow transplantation within the last one-year, Diffuse alveolar hemorrhage from vasculitis, Chronic respiratory failure, Burns \> 70% total body surface)
✕. Previous hypersensitivity or anaphylactic reaction to Cisatracurium
✕. Neuromuscular conditions that may potentiate neuromuscular blockade and/or impair effective spontaneous ventilation

What they're measuring

Duration on mechanical ventilation

Timeframe: Up to 10 days

Trial details

NCT IDNCT05153525

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-07-30

Contact for this trial

Mohamed Khaled Talaat, PharmD

00201067967640 mohamedktalaat@pharm.tanta.edu.eg

View on ClinicalTrials.gov More Respiratory Distress Syndrome, Pediatric trials